Literature DB >> 19372318

The role of tissue factor and factor VIIa in hemostasis.

Nigel Mackman1.   

Abstract

Tissue factor (TF) is a transmembrane receptor for Factor VII/VIIa (FVII/VIIa). It is constitutively expressed by cells surrounding blood vessels. The endothelium physically separates this potent "activator" from its circulating ligand FVII/FVIIa and prevents inappropriate activation of the clotting cascade. Breakage of the endothelial barrier leads to exposure of extravascular TF and rapid activation of the clotting cascade. TF is also expressed in certain tissues, such as the heart and brain, and provides additional hemostatic protection to these tissues. Small amounts of TF are also present in blood in the form of microparticles, which are small membrane vesicles derived from activated and apoptotic cells. Levels of microparticle TF increase in a variety of diseases, such as sepsis and cancer, and this so-called "blood-borne" TF may contribute to thrombosis associated with these diseases. Recombinant FVIIa has been developed as an effective hemostatic drug for the treatment of hemophilia patients with inhibitory antibodies. In addition, it is used for patients with bleeding that do not respond to conventional therapy. However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372318      PMCID: PMC2838713          DOI: 10.1213/ane.0b013e31819bceb1

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  51 in total

Review 1.  The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.

Authors:  C van't Veer; K G Mann
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

2.  Recombinant factor VIIa: a general hemostatic agent? Yes.

Authors:  H R Roberts
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

3.  Mechanism of factor VIIa-dependent coagulation in hemophilia blood.

Authors:  Saulius Butenas; Kathleen E Brummel; Richard F Branda; Sara G Paradis; Kenneth G Mann
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  Haemostatic factors in human peripheral afferent lymph.

Authors:  G J Miller; D J Howarth; J C Attfield; C J Cooke; M N Nanjee; W L Olszewski; J H Morrissey; N E Miller
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

5.  Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction.

Authors:  R Pawlinski; A Fernandes; B Kehrle; B Pedersen; G Parry; J Erlich; R Pyo; D Gutstein; J Zhang; F Castellino; E Melis; P Carmeliet; G Baretton; T Luther; M Taubman; E Rosen; N Mackman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

Review 6.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 7.  Role of tissue factor in hemostasis, thrombosis, and vascular development.

Authors:  Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-29       Impact factor: 8.311

8.  Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia.

Authors:  Rafal Pawlinski; Brian Pedersen; Gernot Schabbauer; Michael Tencati; Todd Holscher; William Boisvert; Patricia Andrade-Gordon; Rolf Dario Frank; Nigel Mackman
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

9.  How factor VIIa works in hemophilia.

Authors:  S Butenas; K E Brummel; B A Bouchard; K G Mann
Journal:  J Thromb Haemost       Date:  2003-06       Impact factor: 5.824

10.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.

Authors:  Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

View more
  70 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

Review 3.  Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Authors:  Boris Arbit; Jonathan C Hsu
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 4.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

Review 5.  Microparticles in hemostasis and thrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 6.  Emergency reversal of anticoagulation: novel agents.

Authors:  Michael Levine; Joshua N Goldstein
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

7.  Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke.

Authors:  Shaobin Wang; Brandi Reeves; Erica M Sparkenbaugh; Janice Russell; Zbigniew Soltys; Hua Zhang; James E Faber; Nigel S Key; Daniel Kirchhofer; D Neil Granger; Nigel Mackman; Rafal Pawlinski
Journal:  JCI Insight       Date:  2016-07-21

8.  Novel anticoagulants in atrial fibrillation stroke prevention.

Authors:  Nicholas B Norgard; James J Dinicolantonio; Taylor J Topping; Benjamin Wee
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

9.  Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.

Authors:  Pierre-Emmanuel Rautou; Kohei Tatsumi; Silvio Antoniak; A Phillip Owens; Erica Sparkenbaugh; Lori A Holle; Alisa S Wolberg; Anna K Kopec; Rafal Pawlinski; James P Luyendyk; Nigel Mackman
Journal:  J Hepatol       Date:  2015-08-29       Impact factor: 25.083

Review 10.  Target specific oral anticoagulants in the management of thromboembolic disease in the elderly.

Authors:  Surekha Maddula; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.